Roche today reported positive Phase III results for Gazyva (obinutuzumab) in adults with systemic lupus erythematosus (SLE) receiving standard therapy. The ALLEGORY study met its main goal, showing more patients achieved a four-point improvement...
Takeda has completed its seven-year Phase 3 TIDES trial of QDENGA confirming that the vaccine provides lasting and reliable protection against dengue. The study, which also looked at the effects of a booster dose, showed that QDENGA maintains...
Johnson & Johnson MedTech, a cardiac arrhythmia treatment global leader, said that new clinical and real-world results of its VARIPULSE™ Platform in pulsed field ablation (PFA) of atrial fibrillation (AF) would be revealed at the Asia Pacific...
Eli Lilly's Omvoh (mirikizumab) shows early and lasting relief in bowel urgency for patients with ulcerative colitis, reducing severity and frequency by over 50 percent in the Phase 3b LUCENT URGE study.
.png)
Lupin Digital Health, India’s leading cardiac digital-therapeutics company, has launched VITALYFE, an AI-powered cardiometabolic wellness platform designed to help India’s professionals improve their heart health...
Roche today announced that it has been awarded CE mark for its Elecsys Dengue Ag test, a high-throughput, completely automated immunoassay intended to support the diagnosis of acute dengue virus infection. This achievement represents a...
Merck & Co. and Eisai Co., Ltd. reported that their kidney cancer drug combo of Welireg and Lenvima met one main goal in a late stage trial for advanced renal cell carcinoma. The combo showed a significant improvement in progression free...
GSK has signed a global exclusive deal with Syndivia - a privately-held biotech dedicated to developing next-generation antibody-drug conjugates (ADCs) - for the advancement and commercialization of a preclinical ADC for patients with metastatic...
According to Novartis' announcement, APPLAUSE-IgAN randomized Phase III trial results have provided positive final results showing that Fabhalta (iptacopan) was demonstrated to significantly slow decline in kidney function in adults with IgA...
.png)
AstraZeneca's Imfinzi (durvalumab) has demonstrated a significant increase in survival for early-stage gastric (GC) and gastroesophageal junction cancers (GEJC), according to new data from the European Society for Medical Oncology (ESMO) 2025...
.jpg)
, CDSCO.jpg)